LY2775240 / Eli Lilly - LARVOL DELTA

Characterization of LY2775240, a Selective Phosphodiesterase-4 Inhibitor, in Nonclinical Models and in Healthy Subjects. (PubMed, Clin Transl Sci) - "The comparator apremilast achieved peak inhibition of ~50% at only 4 hours post-dose with a return to about 10% inhibition within 12 hours of dosing. In summary, the nonclinical data and safety, tolerability and pharmacokinetic/pharmacodynamic data in healthy subjects supports further investigation of LY2775240 in inflammatory indications."

Clinical • Journal • Dermatology • Immunology • Inflammation • Pain • Psoriasis

Phase I Evaluation of the PDE4 Inhibitor LY2775240: Head to Head Comparison with Apremilast Using an Ex Vivo Pharmacodynamic Assay (ACR-ARHP 2019) - "The 20 mg dose of LY2775240 demonstrated an increased and sustained inhibition of PDE4 activity over 24 hours when compared to the clinical dose of apremilast. Inhibition of PDE4 using an ex vivo PD assay with LPS as the stimulus. Data for n=11 subjects shown."

Head-to-Head • P1 data • PK/PD data

Cost-Effectiveness of Targeted Pharmacotherapy for Moderate to Severe Plaque Psoriasis. (PubMed, J Manag Care Spec Pharm) - "Our findings suggest that initial targeted treatment with IL-17 inhibitors is the most effective treatment strategy for plaque psoriasis patients who have failed methotrexate and phototherapy. Apremilast, brodalumab, infliximab, ixekizumab, and secukinumab are cost-effective at different willingness-to-pay thresholds. Additional research is needed on whether the effectiveness of targeted agents changes when used after previously targeted agents."

HEOR • Journal